Field report SE-92 / M4 · sheet /leadership
CEO LeadershipFiled from the territory
White House Pulls Heidi Overton's FDA Commissioner Nomination
The White House pulled Heidi Overton's FDA nomination a day before the Senate HELP Committee's Wednesday vote, leaving the agency without a permanent commissioner.
- Grid
- SE-92 / M4
- Surveyed
- November 18, 2026
- Reading
- 3 min read
- Correspondent
- Priya Raman

Field notes
- The White House withdrew Overton's FDA nomination on Tuesday, one day before a scheduled Wednesday Senate HELP Committee session.
- Overton, a physician and Domestic Policy Council deputy director, was tapped to replace acting Commissioner Kyle Diamantas after Marty Makary's ouster in May.
- HELP Chairman Bill Cassidy called her role in childhood vaccine reforms "almost disqualifying."
- MAHA supporters criticized her for favoring the health and agriculture industries over Kennedy's priorities.
The White House has withdrawn Heidi Overton's nomination to lead the Food and Drug Administration, pulling her name one day before the Senate committee that oversees health policy was set to consider her. The decision lands the agency in fresh leadership limbo, its top job now unsettled for the second time since spring.
A White House official confirmed the move to the Washington Examiner on Tuesday with a terse statement: "Can confirm nomination pulled." No replacement nominee was announced.
Who is Heidi Overton — and why did she stumble?
Overton is a physician and deputy director of the White House Domestic Policy Council, the in-house policy shop that coordinates the administration's domestic agenda. President Donald Trump nominated her to replace acting Commissioner Kyle Diamantas, who took over after his predecessor, Marty Makary, was pushed out in May.
Her nomination collapsed under pressure from three directions at once, each tied to a different faction inside the president's own coalition.
- MAHA movement frustration. Supporters of Health and Human Services Secretary Robert F. Kennedy Jr.'s MAHA movement — short for "Make America Healthy Again," Kennedy's food-and-health reform agenda — criticized Overton for not advancing his priorities. Instead, they argued, she was helping the health and agriculture industries those priorities target.
- Anti-abortion opposition. Anti-abortion activists scrutinized what they saw as her lack of commitment to stricter rules limiting access to the abortion pill mifepristone, a drug the movement wants tightly regulated.
- A chairman's warning. Senator Bill Cassidy of Louisiana, the Republican chairman of the Health, Education, Labor and Pensions Committee, amplified complaints from committee Democrats about Overton's role in the administration's changes to childhood vaccine recommendations. He called her involvement there "almost disqualifying" and had voiced "strong concerns" ahead of the Wednesday session.
That committee, known as HELP, was scheduled to take up her nomination on Wednesday. The withdrawal removes her from that docket before a vote could happen.
Why does the FDA keep churning leaders?
The mechanism here is straightforward: the FDA commissioner job requires Senate confirmation, and this nomination failed to hold together the coalition needed to get there. Overton's exit marks the second leadership rupture at the agency in barely three months.
Makary, her would-be predecessor, left in May after his own standoff with the White House. He had declined to authorize fruit-flavored electronic cigarettes, an outcome the administration wanted, because the sweet flavors could appeal to children. He also faced criticism for delaying restrictions on online prescriptions for mifepristone — the same drug issue that later dogged Overton.
So the pattern repeats. Each commissioner candidate gets squeezed between the White House's policy demands and the political factions, from MAHA loyalists to anti-abortion groups, that police them. Overton's nomination broke on exactly those fault lines: vaccine policy, mifepristone access, and industry influence.
What happens now?
For the moment, nothing changes on paper. Diamantas remains acting commissioner, and the agency continues to operate under interim leadership. The White House has not named a new candidate, which means a fresh nomination, a new confirmation fight, and more weeks — likely months — before a permanent commissioner takes the post.
The political math for any successor is unenviing. They will need to satisfy a president who wants specific outcomes on flavored vapes and abortion-pill regulation, an HHS secretary pushing MAHA priorities, and a Senate chairman who has already shown he will call a nominee's record "almost disqualifying" in public.
Whoever comes next inherits that triangle. And the FDA, which regulates everything from prescription drugs to e-cigarettes, waits.
via washingtonexaminer.com (Source)
More from Priya Raman
Show full bio
Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.
460 articles
Adjacent sheets
- Senators Demand HHS Action on Prediction Markets Tied to Drug Trials
- Kennedy urges GOP action on drug pricing after two-year lapse
- Trump Backs Duffy and Lutnick Amid FAA Outage and Nvidia Export Fight
- DEI’s post-midterm comeback will hinge on trust, not announcements
- Voters Want an AI Pause, Not Just Data Center Limits, Researcher Warns